vimarsana.com
Home
Live Updates
Data from Newrons study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS) -April 08, 2024 at 01:02 am EDT : comparemela.com
Data from Newron's study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS) -April 08, 2024 at 01:02 am EDT
EQS-News: Newron Pharmaceuticals S.p.A.
/ Key word: Study results
Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual...
Related Keywords
Israel ,
Australia ,
Canada ,
Bresso ,
Lombardia ,
Italy ,
Germany ,
Milan ,
Switzerland ,
Seika ,
Kyongsang Bukto ,
South Korea ,
Sri Lanka ,
United States ,
United Kingdom ,
Japan ,
India ,
United Arab Emirates ,
America ,
Stefan Weber ,
Anne Hennecke Caroline Bergmann ,
Valentin Handschin ,
Paul Sagan ,
Schizophrenia International Research Society ,
European Union ,
Mc Services ,
Supernus Pharmaceuticals ,
Newron Pharmaceuticals ,
Negative Syndrome Scale ,
Clinical Global Impression ,
Strauss Carpenter Level ,
Latin America ,
Meiji Seika ,
Ciara Martin ,
Natalie Garland Collins ,
Caroline Bergmann ,
Markets ,
comparemela.com © 2020. All Rights Reserved.